Frequent amyloid deposition without significant cognitive impairment among the elderly

Archives of Neurology

Volumn 65, Issue 11, 2008, Pages 1509-1517

  Aizenstein, Howard Jay ^a   Nebes, Robert D ^a   Saxton, Judith A ^a   Price, Julie C ^a   Mathis, Chester A ^a   Tsopelas, Nicholas D ^a   Ziolko, Scott K ^a   James, Jeffrey A ^a   Snitz, Beth E ^a   Houck, Patricia R ^a   Bi, Wenzhu ^a   Cohen, Ann D ^a   Lopresti, Brian J ^a   DeKosky, Steven T ^a   Halligan, Edythe M ^a   Klunk, William E ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID;

AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DEMOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALLELES; AMYLOID; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BRAIN; COGNITION; FEMALE; HETEROZYGOTE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; REFERENCE VALUES; THIAZOLES;

EID: 55949117032     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.11.1509     Document Type: Article

References (49)

1. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 1992;13(1):179-189.
2. Haroutunian V, Perl D, Purohit D, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer's disease. Arch Neurol. 1998;55(9):1185-1191.
3. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358-368.
4. Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun Study. Alzheimer Dis Assoc Disord. 1999;13(4):226-231.
5. Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60(10):1385-1389.
6. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119-1122.
7. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
8. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(pt 6):1630-1645.
9. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-β (Aβ) peptide-related cerebral amyloidosis. Brain. 2007;130(pt 10):2607-2615.
10. Rabbitt P. Does it all go together when it goes? the 19th Bartlett Memorial Lecture. Q J Exp Psychol A. 1993;46(3):385-434.
11. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.
12. Cummings BJ, Cotman CW. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 1995;346(8989):1524-1528.
13. Nielson KA, Cummings BJ, Cotman CW. Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Brain Res. 1996;96(1-2):284-293.
14. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl. 1998;53:127-140.
15. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572-580.
16. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound-B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959-1972.
17. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67 (3):446-452.
18. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725.
19. Nebes RD, Meltzer CC, Whyte EM, et al. The relation of white matter hyperintensities to cognitive performance in the normal old: education matters. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2006;13(3-4):326-340.
20. Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology. 2000;55(12):1854-1862.
21. The Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Arlington, VA: American Psychiatric Association; 1994.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
23. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review); Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133-1142.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
25. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(9):1159-1165.
26. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch Psychol. 1941;28:286-340.
27. Reitan RM. Validity of the Trail-making Tests as an indication of organic brain damage. Percept Mot Skills. 1958;8:271-276.
28. Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology. 2000;55(12):1863-1869.
29. Freedman M. Clock Drawing: A Neuropsychological Analysis. Oxford, England: Oxford University Press; 1994.
30. Saxton J, Ratcliff G, Newman A, et al. Cognitive test performance and presence of subclinical cardiovascular disease in the Cardiovascular Health Study. Neuroepidemiology. 2000;19(6):312-319.
31. Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6:53-60.
32. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135-140.
33. Wechsler D. Wechsler Test of Adult Reading. New York, NY: Psychological Corporation; 2001.
34. Dobbs AR, Rule BG. Adult age differences in working memory. Psychol Aging. 1989;4(4):500-503.
35. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. New York, NY: Psychological Corporation; 1997.
36. Spieler DH, Balota DA, Faust ME. Stroop performance in healthy younger and older adults and in individuals with dementia of the Alzheimer's type. J Exp Psychol Hum Percept Perform. 1996;22(2):461-479.
37. Burgess PW, Shallice T. Response suppression, initiation, and strategy use following frontal lobe lesions. Neuropsychologia. 1996;34(4):263-272.
38. Weinhard K. Applications of 3D PET. In: Bendriem B, Townsend D, eds. The Theory and Practice of 3D PET. Boston, MA: Kluwer Academic Publishers; 1998:133-167.
39. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci. 2000;47(4):1587-1594.
40. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528-1547.
41. Schwertman NC, de Silva R. Identifying outliers with sequential fences. Comput Stat Data Anal. 2007;51(8):3800-3810.
42. Ziolko SK, Weissfeld LA, Klunk WE, et al. Evaluation of voxel-based methods for the statistical analysis of PiB PET amyloid imaging studies in Alzheimer's disease. Neuroimage. 2006;33(1):94-102.
43. Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline. JAMA. 2000;283(12):1571-1577.
44. Pike KE, Savage G, Villemagne VL, et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130(pt 11):2837-2844.
45. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
46. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58(4):376-388.
47. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087-1095.
48. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 2006;60(6):688-695.
49. Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology. 2001;56(3):361-367.